((自动化翻译由路透提供，请见免责声明 ))
10月1日 - ** Biohaven 股价盘前下跌 2.4%，至 48.75 美元。
** 生物制药公司以 47.50 美元的价格出售 (link) ~530 万股股票，筹集 2.5 亿美元用于一般用途
** 发行价较股票最后收盘价折价 4.9
** 摩根大通、摩根士丹利、Jefferies 和 TD Cowen 作为账簿管理人
** 9 月 23 日，BVHN 上涨约 14%，报收于 45.94 美元，因为该公司的药物 troriluzole 在一项针对脊髓小脑共济失调$(SCA)$ 的研究中达到了主要目标 (link)，这种遗传性神经退行性疾病主要影响小脑。
** 该公司拥有约 9 450 万股已发行股票，市值为 47 亿美元（根据伦敦证交所数据）。
** 截至周一收盘，该公司股价年累计上涨约 17%，在过去 12 个月中几乎翻了一番
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.